Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update

Table 2

Initial risk assessment for febrile neutropenic patients (adapted from NCCN guideline) [7].

Low risk (score > 21 on the MASCC risk score) OR:	High risk (score < 21 on the MASCC risk score) OR:
Outpatient status at time of development of fever	Inpatient status at time of development of fever
No associated acute comorbid illness	Significant medical comorbidity or clinically unstable
Anticipated short duration of severe neutropenia (less than 7 days)	Anticipated prolonged severe neutropenia (ANC < 100 cells and >7 days)
Good performance status (ECOG 01)	Hepatic insufficiency
No hepatic insufficiency	Renal insufficiency
No renal insufficiency	Pneumonia or other complex infections at clinical presentation
	Alemtuzumab
	Mucositis grade 3-4